 GAITHERSBURG, Md. BURLINGAME, Calif.--BUSINESS WIRE--Emergent BioSolutions Inc. NYSE:EBS Emergent and Humanigen, Inc. NASDAQ:HGEN Humanigen today announced that they have entered into a contract development and manufacturing CDMO services agreement to accelerate the drug product manufacturing of lenzilumabTM, an anti-human granulocyte macrophage-colony stimulating factor GM-CSF monoclonal antibody designed to prevent and treat an immune hyper-response called cytokine storm. Eme 